Therefore, pharmacological inhibitors of the VEGF/VEGFR-2 pathway inhibit tumor angiogenesis to limit tumor growth by blocking the nutrient and oxygen supply and restore structural and functional vascular integrity, termed vascular normalization, leading to improved drug delivery and therapeutic efficacy. This evidence concerns the gene KDR and neoplasm.